News | August 23, 2011

UltraSPECT Dose NM/PET Reduction Systems Installed at Multiple Sites

August 23, 2011— UltraSPECT of Haifa, Israel, announced the sale of more than 10 of its wide beam reconstruction (WBR) software solutions to nuclear pharmaceutical supplier PCI for placement at customer medical facilities throughout Arizona. PCI is a member of United Pharmacy Partners Inc. (UPPI), a nuclear pharmacy network consortium that recently signed a multi-year distribution agreement for the leasing and/or non-exclusive sales of UltraSPECT’s cardiac and bone imaging applications in the United States.

WBR is an innovative technology addressing current concern about patient radiation exposure. It enhances the performance of gamma cameras and PET scanners to enable a 50 percent reduction in injected dose and/or imaging procedure time with no decrease in image quality and while enhancing image resolution.

WBR’s lower dose requirements offer the benefits of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users, the result is enhanced equipment utilization, revenues, patient satisfaction and referrals.

UltraSPECT’s enhanced WBR can either cut 50 percent of standard radiopharmaceutical dose requirements or reduce imaging scan time to a quarter of what it was before, while maintaining full image quality. The most recent WBR application allows both reduction in dose and scan time. This technology can be utilized with most major manufacturers’ nuclear medicine (NM) and positron emission tomography (PET) systems, as well as all clinical software packages.

Tri-City Cardiology Consultants of Mesa, Ariz., recently acquired the technology through PCI. Commenting on its recent WBR installation, Michelle Smudde, office manager at the cardiology group, said, "WBR technology has been easily accepted by our physicians and technologists. The implementation of the software among our fellow practices went pretty quickly." 

Ridge Smidt, Pharm D., owner of PCI Nuclear Pharmacy, added, “The Tri-City WBR installation demonstrates the power of WBR in reducing patient radiation exposure without sacrificing image quality and diagnostic accuracy. If all our nuclear medicine customers were to adopt the technology and incorporate WBR into their general practice, everyone involved would benefit – patients, physicians, technologists, pharmacies and pharmacy staff.”

For more information: www.ultraspect.com, www.pcinuclear.com

 

Related Content

Researchers Trace Parkinson's Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init